Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Key facts
- Who runs it
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Where
- Burkina Faso, Gabon, Mozambique, and Uganda5 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 38 people enrolled
- Started
- 29 Mar 2023
- Ended
- 28 May 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- M5717 330 mg
- M5717 500 mg
- M5717 660 mg
- Pyronaridine 360 mg
- Pyronaridine 540 mg
- Pyronaridine 720 mg
- Record updated
- 27 August 2025
Who can take part
- Age
- 12 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
- P. falciparum parasitemia of 1,000 to 50,000 asexual parasites/microliter of blood in Part A and P. falciparum parasitemia of >1,000 to <= 150,000 asexual parasites/microliter of blood in Part B
- Axillary temperature >= 37.5 degree Celsius or tympanic temperature >= 38.0 degree Celsius (use as per Coronavirus disease 2019 (COVID-19) protocols at the site [only at Screening]), or history of fever during the previous 24 hours (at least documented verbally)
- The Investigator confirms that each participant agrees to use appropriate contraception and barriers, if applicable
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and this protocol
- Other protocol defined inclusion criteria could apply
Who cannot take part
- Previous treatment with pyronaridine as part of a combination therapy during the last 3 months
- Prior antimalarial therapy or antibiotics with antimalarial activity within a minimum of their 5 plasma half-lives (or within 4 weeks of Screening if half-life is unknown)
- Participants taking medications prohibited by the protocol
- Mixed Plasmodium infections as per thin film microscopy results
- Known liver abnormalities, liver cirrhosis (compensated or decompensated), known active or history of hepatitis B or C (testing not required), underlying hepatic injury or known severe liver disease, known gallbladder or bile duct disease, acute or chronic pancreatitis, or severe malnutrition
- Known history or evidence of clinically significant disorders such as, cardiovascular, respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological [including known Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS)], neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions, or other abnormality (including head trauma)
- Signs and symptoms of severe malaria according to World Health Organisation (WHO) 2021 criteria (WHO 2021)
- Other protocol defined exclusion criteria could apply
Where is this trial?
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
The 2 groups in the trial
- Part A: Safety Run-in Cohort M5717+PyronaridineTreatment being tested
M5717 and pyronaridine once daily in a single day treatment regimen at low dose of 330 milligrams (mg) and 360 mg respectively.
Treatment: M5717 330 mg and Pyronaridine 360 mg
- Part B: Dose escalation cohort; M5717+PyronaridineTreatment being tested
After completion of Part A, if dose will be considered safe and well tolerated, the Internal Data Monitoring Committee (IDMC) will have the option to recommend dose adjustments. M5717 and pyronaridine once daily will be administered in an escalated dose in a single day or 2-day treatment regimen.
Treatment: M5717 500 mg, M5717 660 mg, Pyronaridine 360 mg, Pyronaridine 540 mg, and Pyronaridine 720 mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
- Publications
- Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study.The Lancet. Infectious diseases, 2026
- Record updated
- 27 August 2025